

THOMAS ERSKINE FEASBY
CM BSc(MED) MD FRCPC DSC(HON) ICD.D

PROFESSOR OF NEUROLOGY
& PAST DEAN
CUMMING SCHOOL OF MEDICINE
UNIVERSITY OF CALGARY

ROOM 3D08, TRW BUILDING
3280 HOSPITAL DRIVE NW
CALGARY, ALBERTA
CANADA T2N 4Z6

PHONE – 403-220-7663
FAX- 403-270-7307
EMAIL – feasby@ucalgary.ca

Place of Birth: Halifax, Nova Scotia, Canada

Citizenship: Canadian

EDUCATION

1969 University of Manitoba
B.Sc. (Med.), M.D.

SPECIALIST QUALIFICATIONS

1982 Certified by the American Board of Neurology and Psychiatry

1974 F.R.C.P.C. Neurology

RESIDENCY AND OTHER GRADUATE TRAINING

1975-77 Research Fellow (with Professor T.A. Sears)
Sobell Department of Neurophysiology, Institute of Neurology
Queen Square
London, England

1970-74 Resident in Neurology (with Dr. H.J.M Barnett) and Internal Medicine
University of Western Ontario
London, Ontario

Revised January 2018

- 1969-70 Internship
Toronto Western Hospital
Toronto, Ontario
- 2012-13 Institute of Corporate Directors, Directors' Education Program (ICD.D)

ACADEMIC POSITIONS

- 2007- Professor of Neurology
Departments of Clinical Neurosciences and Community Health Sciences
Member of the O'Brien Institute for Public Health and the Hotchkiss Brain
Institute
University of Calgary
- 2003-07 Professor of Neurology
University of Alberta
- 2002-03 Health Research Consultant
1997-98 RAND Corporation
Santa Monica, CA
(while on sabbatical)
- 1991- 2003 Professor of Neurology
Department of Clinical Neurosciences
University of Calgary
- 1988 Professor of Neurology
Department of Clinical Neurological Sciences
University of Western Ontario
- 1982 Associate Professor of Neurology
Department of Clinical Neurological Sciences
University of Western Ontario
- 1977 Assistant Professor of Neurology
Department of Clinical Neurological Sciences
University of Western Ontario

MAJOR LEADERSHIP POSITIONS

- 2017 Chief Executive Officer, Airdrie and Area Health Benefits Cooperative
- 2007-2012 Dean, Faculty of Medicine, University of Calgary
- 2003-2007 Vice-President Academic Affairs, Capital Health, Edmonton

- 2003-07 Associate Dean Clinical Affairs, Faculty of Medicine and Dentistry, University of Alberta
- 1991-2002 Head, Department of Clinical Neurosciences, University of Calgary
Head, Regional Department of Clinical Neurosciences, Calgary Health Region
- 1988-91 Chief, Department of Clinical Neurological Sciences, Victoria Hospital, London, Ontario.

AWARDS AND HONOURS

- 2017 Appointed as a Member of the Order of Canada
- 2016 Rhodes Trust Inspirational Educator Award, 2016
- 2015 Outstanding Service Award from the O'Brien Institute for Public Health, University of Calgary
- 2014 Medal for Distinguished Service, presented by the Alberta Medical Association, September 19, 2014
- 2013 Honourary Doctor of Science degree conferred by Western University on November 1, 2013
http://www.youtube.com/watch?v=3Ag76sBo2vs&list=PLbZM4TW_GWGTGxcmf6loMSDewWgwg6s4-&index=3
- 2012 Tom Feasby Graduate Award in Global Health created in the Cumming School of Medicine, University of Calgary. This is a graduate training award for promising health leaders from low and middle income countries.
- 2012 Feasby Student Lounge created and named in the Cumming School of Medicine, University of Calgary
- 2012 Thomas E Feasby Studentships and Fellowships, created and funded by the Alberta Stroke Program
- 2012 Convocation address, University of Calgary, June 7, 2012
http://www.youtube.com/watch?v=w_f6JOHZCII
- 2011- International Consultant of Capital Medical University, Beijing, China
- 2007 Tom Marrie Mentorship Award, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta

2006	Elected to the Canadian Academy of Health Sciences
1983-84	President, London Medical Historical Association
1982-84	Honourary President, University of Western Ontario Medical Class of 1984
1975-77	Centennial Fellow, Medical Research Council of Canada

MEMBERSHIP IN PROFESSIONAL SOCIETIES

Canadian Medical Association
Alberta Medical Association
Canadian Neurological Society
Alberta Neurological Association
American Academy of Neurology
American Neurological Association
Canadian Association of Health Services and Policy Research

BOARDS of DIRECTORS

2015-	Board of Directors of the Heart and Stroke Foundation of Canada and member of the Research Committee and the Governance Committee
2014-17	Board of Directors of the Alberta Medical Foundation
2013-	Board of Directors of the Multiple Sclerosis Society of Canada, and member of the Medical Advisory Committee
2012-	Strategic Advisory Board, O'Brien Institute for Public Health, Cumming School of Medicine, University of Calgary (Interim Chair , 2015)
2011-17	Chair (2011-2015) , Scholars' Academy Program Advisory Council, University of Calgary
2010-17	Quality and Safety Advisory Committee, Alberta Health Services Board
2007-12	Board of Directors, Association of Faculties of Medicine of Canada, Chair , 2011-1012
2007-12	Council, College of Physicians and Surgeons of Alberta
2008-17	Board of Directors of the Michael Smith Foundation for Health Research, British Columbia, and member of the Audit Committee (2010-17), the

	Human Resources and Governance Committee (2013-15), and the Executive Committee (2013-15)
2006-08	Board of Directors of the CIHR Institute of Health Services and Policy Research
2006-12	Board of Directors, Institute of Health Economics
2007-08	Board of Directors, Calgary Health Region
2007	Board of the Children's and Women's Health Research Institute, University of Alberta, Edmonton
2005-07	Advisory Board, Alberta Diabetes Institute
2005-07	Board of Directors, Research Canada
1999- 2003	Board of Directors of the American Academy of Neurology
1993-95	Council, American Neurological Association
1984-87	Council, Canadian Neurological Society

HOSPITAL AND UNIVERSITY COMMITTEES

2015-	Advisory Committee for the Multiple Sclerosis Translational Clinical Trials Program, Cumming School of Medicine, University of Calgary
2015-	Department of Community Health Sciences Advisory Committee, Cumming School of Medicine
2014-16	Chair , Cumming School of Medicine Accreditation Committee for Undergraduate Medical Education, University of Calgary
2014-	Leadership Training Advisory Team, Cumming School of Medicine, University of Calgary
2013-17	Director , Hotchkiss Brain Institute Mentorship Program for Clinician-Scientists, University of Calgary
2012-14	NIH Financial Conflict of Interest Committee, University of Calgary
2012-	Awards and Recognition Committee, Faculty of Medicine
2011-	Rhodes Scholar Candidate Preparation Committee, University of Calgary

2010-11	Strategy Steering Committee for the University of Calgary (Produced the current University of Calgary strategic plan <i>Eyes High</i>)
2010-11	Search and selection committee for the new Provost of the University of Calgary
2009-10	Search and selection committee for the new President of the University of Calgary
2007-12	Chair , Dean's Executive Committee, Faculty of Medicine, University of Calgary
2007-12	Deans' Council, University of Calgary
2007-12	Chair , Leadership Forum, Faculty of Medicine, University of Calgary
2006-07	Chair , Search and Selection Committees for the Capital Health Research Chairs in Primary Care, Aboriginal Health, Cardiac Disease, and Transplant
2006-7	Chair , Search and Selection Committees for the Capital Health/University of Alberta Clinical Scientists in Nursing and Rehabilitation Medicine
2005-6	Chair , Capital Health/University of Alberta, CFI/Research Hospital Fund Steering Committee
2005	Chair , Search and Selection Committee for Director, Northern Alberta Clinical Trials and Research Centre
2005	Chair , Search and Selection Committee for Scientific Director, iCARE
2005-6	Search and Selection Committee for Scientific Director, Mazankowski Alberta Heart Institute
2005-7	Capital Health/Faculty of Medicine and Dentistry Joint Council
2005-6	Chair , Search and Selection Committee for the Capital Health Research Chair in Health Informatics
2005	Review Committee, Chair of Family Medicine, University of Alberta
2005	Search and Selection Committee for the Associate Dean Continuous Professional Learning, Faculty of Medicine and Dentistry
2005	Search and Selection Committee for the Associate Dean Research, Faculty of Medicine and Dentistry

- 2003-7 Regional Quality Council, Capital Health
- 2004-7 Health Policy and Management Professional Program Advisory Committee, Department of Public Health Sciences, University of Alberta
- 2003-6 Search Committee for the Chair, Department of Surgery, University of Alberta
- 2003-7 Alberta Diabetes Institute Research Coordinating Committee, Faculty of Medicine and Dentistry, University of Alberta
- 2003-7 Alberta Heart Institute Steering Committee, University of Alberta and Capital Health
- 2003-7 Clinical Information System Steering Committee, Capital Health
- 2003-7 Joint Liaison and Operations Council, University of Alberta and Capital Health
- 2003-7 Health Sciences Council, University of Alberta
- 2003-7 Dean's Executive Committee, Faculty of Medicine and Dentistry, University of Alberta
- 2003-7 Faculty Evaluation Committee, Faculty of Medicine and Dentistry, University of Alberta
- 2003-7 Research Advisory Committee, Faculty of Medicine and Dentistry, University of Alberta
- 2003-7 Faculty Education Advisory Committee, Faculty of Medicine and Dentistry, University of Alberta
- 2003-7 Department Chairs and Divisional Directors Committee, Faculty of Medicine and Dentistry, University of Alberta
- 2003-7 **Co-chair**, Health Research Ethics Administration Board, University of Alberta
- 2003-07 **Chair**, Northern Alberta Clinical Trials Research Centre Management Board
- 2003- 07 **Co-Chair**, Glenrose Hospital Research Committee
- 2003-07 Stroke Steering Committee, University of Alberta Hospital
- 2003-07 Regional Medical Advisory Committee, Capital Health

2003-07	Capital Health Executive, Capital Health
2003-07	Direct Reports Committee, Capital Health
2003-05	Chair , Planning Committee for the Centre for Health Outcomes Research (iCARE), University of Alberta and Capital Health
2003-04	Search Committee for the Chair of Medicine, Faculty of Medicine and Dentistry, University of Alberta and Capital Health
2002	Search Committee for the Sware Chair in Health Economics, University of Calgary
2000-02	Search Committee for the Head of the Department of Medicine, University of Calgary and the Calgary Health Region
2000-02	Physician Partnership Steering Committee, Calgary Health Region
1999-2002	Awards Committee, Faculty of Medicine, University of Calgary
1997-2002	Medical Leadership Team, Calgary Regional Health Authority
1997-2002	Regional Medical Advisory Board, Calgary Regional Health Authority
1996-97	Search Committee for the Dean of Medicine, University of Calgary
1995-97	Recruitment Priorities Committee, Faculty of Medicine, University of Calgary
1993-95	Executive Committee, Faculty Council, Faculty of Medicine, University of Calgary
1991-97	Foothills Hospital Research and Development Committee
1991-94	University of Calgary Medical Clinic, Management Committee
1991-95	Foothills Hospital Ambulatory Care Committee
1991-97	Foothills Hospital Medical Advisory Committee
1990-91	Intercollegiate Athletics Committee, University of Western Ontario
1990-91	Appointments, Promotion and Tenure Committee, Faculty of Medicine, University of Western Ontario
1990	Chair , Selection Committee for Chief of Nuclear Medicine, Victoria Hospital, London, Ontario
1990-91	Chair , Victoria Hospital Critical Care Coordinating Committee

1989-91	Member of the Senate, The University of Western Ontario
1989-91	Selection Committee for Chairman, Department of Clinical Neurological Sciences, The University of Western Ontario
1988-91	Victoria Hospital, MRI Committee
1988-91	Victoria Hospital, Medical Advisory Committee Executive
1988-91	Victoria Hospital, Medical Advisory Committee, London, Ontario
1985-91	Appointments and Promotion Committee, Department of Clinical Neurological Sciences, University of Western Ontario
1987-88	University Hospital Admission & Discharge Committee
1982-84	Selection Committee for Chair, Department of Clinical Neurological Sciences, University of Western Ontario
1982-86	University Hospital Audit Committee, London, Ontario

PROFESSIONAL AND OTHER COMMITTEES

2014-17	Canadian Academy of Health Sciences, Standing Committee on Assessments
2014	Alberta Health Services' Blue Ribbon Panel on assessing applicants for the redevelopment of laboratory services for AHS in Edmonton
2010-16	Neuroscience Impact Review Panel for the Margolese National Brain Disorders Prize
2010-11	Consultation Advisory Committee, Alberta Health and Wellness, Government of Alberta
2010-11	United Way of Calgary Leaders' Cabinet
2009-10	Minister's Advisory Committee on Health (Ministry of Health and Wellness, Alberta)
2008-12	Governance Committee, Association of Faculties of Medicine of Canada
2008-12	Executive Committee, Association of Faculties of Medicine of Canada
2008-12	Council of Deans, American Association of Medical Colleges

2008-12 Complaint Appeals Committee, Council of Physicians and Surgeons of Alberta

2007-12 Representative Forum, Alberta Medical Association

2007 Canadian Association of Health Services and Policy Research conference planning committee

2006-7 **Chair**, Search Committee for the Research Director of the Canadian Patient Safety Institute (in conjunction with Capital Health and the Faculty of Medicine and Dentistry, University of Alberta)

2006 Health Technology Assessment Strategic Planning Committee, Institute of Health Economics

2006-7 Safety Monitoring Committee, RCT of memantine in ALS, Drs. S Kalra and KM Chan, PIs

2006-12 Audit and Finance Committee, Institute of Health Economics

2006-10 Canada Research Chairs College of Reviewers

2006-7 Alberta Mental Health Research Partnership Committee

2005-7 **Co-chair**, Association of Canadian Academic Healthcare Organizations (ACAHO) Vice-Presidents' Research Committee

2005-06 Third Way Advisory Committee, Alberta Minister of Health and Wellness

2005-07 Research and Evaluation Advisory Committee, Canadian Patient Safety Institute

2005-07 Alberta Diabetes Institute Research Advisory Committee

2004-06 **Co-chair**, Research Advisory Committee, Alberta Ministry of Health and Wellness

2004-05 SEARCH Canada Transitional Advisory Committee

2004- Post Graduate Medical Education Advisory Group, College of Physicians and Surgeons of Alberta

2003-06 Science Committee, American Academy of Neurology

2003- Health Research Advisory Committee, Alberta Heritage Foundation for Medical Research

2002-03	Strategic Plan Oversight Committee, American Academy of Neurology
2002	Nomination Committee, American Academy of Neurology
1999-2001	Implementation and Outcomes Subcommittee, American Academy of Neurology
1998-2004	Outcomes Research Committee, American Neurological Association, Chair , 2000-2004
1998- 2002	Governance and Mandate Committee, Muscular Dystrophy Association of Canada
1993-97	Program Advisory Committee, Alberta Heritage Foundation for Medical Research (Co-Chair 1995-97)
1991-97	Board of Directors, Muscular Dystrophy Association of Canada
1991-97	Medical Advisory Committee, Muscular Dystrophy Association of Canada
1991-93	Program Committee, American Neurological Association
1989-91	Examination Committee in Neurology, Royal College of Physicians and Surgeons of Canada
1989-91	Muscular Dystrophy Association of Canada Fellowship Committee
1987-97	Neuromuscular Disease Research Committee of the World Federation of Neurology
1987-89	Examination Committee in Neuropathology, Royal College of Physicians and Surgeons of Canada
1987-88	Chair , Sub-committee on Neurosciences Research for Ontario Universities' Committee on Health Research
1986-88	Royal College of Physicians and Surgeons of Canada, Specialty Committee in Neurology
1985-86	Task Force on Mental Health, Ontario Ministry of Health
1984-88	Research Committee, Canadian Society of Clinical Neurophysiologists
1978-79	Member, Ontario Ministry of Health Task Force on Pulsed Electrical Stimulation of the Nervous System

GRANT REVIEW COMMITTEES

2016	Canadian Institutes of Health Research special scientific review panel on Zika virus research
2014	Review committee for the Ontario Research Fund Infrastructure Competition, Health Sciences Panel, Toronto
2012-13	Chair , O'Brien Institute for Public Health Internal Review Committee for applications to the AI-HS CRIO competition
2005	Canadian Patient Safety Institute Merit Review Panel
2005	Scientific Officer , Canadian Institutes of Health Research, Grant Review Committee on Research Syntheses: Priority Health Services and Systems Issues
2004-07	Chair , University of Alberta Hospital Foundation Medical Research Competition
2003-04	Canadian Health Services Research Foundation Merit Review Panel
2002-04	Canadian Institutes of Health Research, Health Services Evaluation and Interventions Research Committee A
1998-2002	Chair , Adult Research Committee, Calgary Health Region
1987-97	Muscular Dystrophy Association of Canada, Grant Review Committee, Vice-Chair (1992-94), Chair (1994-97)
1984-87	Research Advisory Committee of the Ontario Deafness Research Foundation
1983-87	Medical Research Council of Canada, Neurosciences A Committee
1979-86	Ontario Ministry of Health Committee on Research Grants

ADMINISTRATIVE CONSULTING AND ACADEMIC INSTITUTIONAL REVIEWS

Review of the Toronto Dementia Research Alliance, University of Toronto, November 28-29, 2017

Review of the Department of Clinical Neurological Sciences, Western University, London, Ontario, November 20-21, 2017

University of Alberta President's Visiting Committee to review the Faculty of Medicine and Dentistry (reporting to the President and the Dean of the Faculty, September 17-19, 2017)

University of Alberta President's Visiting Committee to review the Faculty of Medicine and Dentistry (reporting to the President and the Dean of the Faculty), May 25-27, 2016

The O'Brien Institute for Public Health, University of Calgary. **Chair** of the International Scientific Advisory Group (John Ayanian, Ilse Treurnicht, Fred Paccaud) for the review, March 12-13, 2015

Vancouver Coastal Health Research Institute external review (with Pieter Cullis, Wyeth Wasserman and Christopher Paige), December 16-17, 2014

Institute for Public Health, University of Calgary. **Chair** of the International Scientific Advisory Group (John Ayanian, Ilse Treurnicht, Fred Paccaud) for the review, September 30 – October 1, 2013

Mount Sinai Hospital Department of Medicine (with Dr. D. Anderson), Toronto, June 23, 2013

McGill University, Department of Neurology and Neurosurgery (with Dr. J. Stoessel), Montreal, January 14-15, 2013

Chair, Accreditation Review team for CACMS/LCME of the Undergraduate Medical Education Program at the University of Toronto Faculty of Medicine, May 2012

University of Western Ontario, review of the Faculty of Medicine (with Dr. Cathy Whiteside), May 27-29, 2009

Michael Smith Health Research Foundation, Infrastructure Programs External Review, Vancouver, BC, November 6-7, 2006

Division of Neurology, Department of Medicine, University of British Columbia, September 29-30, 2005

Consultant, Medical Advisory Board, Multiple Sclerosis Society of Canada, Toronto, January 29, 2005.

Department of Clinical Neurological Sciences, University of Western Ontario and the London Health Sciences Centre, January 2004.

The Institute for Clinical Evaluative Sciences (ICES)(with four others), Toronto, January 2003

Division of Neurology, the Ottawa Hospital and the Department of Medicine, University of Ottawa, November 2002

Psychiatric Disorders Research Group, University of Calgary, November 2001

Department of Clinical Neurological Sciences, University of Western Ontario, Academic Review, February 2000

Department of Clinical Neurological Sciences, University of Western Ontario, Operational Review with First Consulting Group, November 1999

Division of Neurology, Department of Medicine, University of British Columbia, November 1998

Henri M. Toupin Chair in Neurological Sciences, University of Alberta, January 1998

Division of Neurology, Department of Medicine, University of British Columbia, December 1993

Division of Neurology, St. Paul's Hospital, Vancouver, British Columbia, April 1993

Department of Clinical Neurosciences, Greater Victoria Medical Society, Victoria, British Columbia, February 1992

Department of Medicine, Victoria Hospital, London, Ontario, May 1990

EDITORIAL BOARDS

1997-2005	Neurology
1995-2005	Journal of the Peripheral Nervous System
1995-2000	Muscle and Nerve
2003-2004	Continuum (American Academy of Neurology)

EXTRAMURAL INVITED LECTURES AND COURSES

Measuring the Quality of Healthcare. Presented at the Canadian Energy Pipeline Quality Summit, Calgary, October 24, 2017

Guillain-Barre Syndrome: the old and the new. Presented at the Western Canadian Neuromuscular Conference, University of Alberta, Edmonton, October 15, 2017

The Axonal Form of Guillain-Barre Syndrome. Presented at the Inflammatory Neuropathy Consortium (INC) meeting in Glasgow, Scotland, June 24, 2016

The Joy of a Life in Medicine. Opening address to Operation Med School (highschool students aspiring to a life in medicine), Calgary, March 20, 2016

Observations on the Role of a Professional Faculty Dean. Presentation to the Symposium on the Changing Role of Professional School Deans, University of Calgary, November 16, 2015

The Tait McPhedran Memorial Lecture, University of Calgary, June 13, 2014: *Improving Surgical Outcomes Through Clinical Trials and Appropriateness Studies*

CSL-Behring Intravenous Immunoglobulin Advisory Panel, Interlaken, Switzerland, April 6, 2014: *The Appropriateness of Intravenous Immunoglobulin*

CIHR Institute of Health Services and Policy Research, 2014 IHSPR Priorities Forum, Toronto, March 31 – April 1, 2014: *How to increase the Canadian capacity for health services research.*

Institute of Health Economics Health Innovation Forum, Edmonton, November 28, 2013: *Overuse of Healthcare Interventions.* <http://www.ihe.ca/research/knowledge-transfer-initiatives/--innovation-forum-series/innovation-forum-x---/>

The 23rd International Magnetic Angiography Workshop, Banff, Alberta, September 26, 2011: *From Clinical Trials to Appropriateness: Doing the right thing.*

The International Symposium on Health Policy and Medical Care System Reform, Harbin Medical University, Harbin, China, June 25, 2011: *The Canadian Health Care System*

The Inaugural Don Paty Memorial Lecture, University of British Columbia, Vancouver, June 1, 2010, *How Can We Do Better in Healthcare?*

Canadian Association of Health Services and Policy Research, Annual Meeting, Calgary, May 12, 2009, opening address: *The Appropriateness of Healthcare Interventions.*

Institute of Health Economics Innovation Forum on Comparative Effectiveness, Edmonton, Alberta, December 2, 2008: *Comparative Effectiveness and Appropriateness*

Canadian Society of Transfusion Medicine, Calgary, Alberta, May 4, 2007: *The Appropriate Use of IVIG in Neurology (and beyond)*

Planning retreat of the Alberta Ministry of Health and Wellness, Edmonton, September 22, 2006: *The Measurement of Quality and Pay for Performance*

CHUV, University of Lausanne, Switzerland, June 23, 2006: *The appropriateness of carotid endarterectomy*

Controversies in Neurology, Lucerne, Switzerland, June 22, 2006: *Idiopathic polyneuropathy*

Canadian Congress of Neurological Sciences, Montreal, June 15, 2006: *Innovation and accountability: the changing landscape for Neurosciences*

Department of Neurology and Neurosurgery, McGill University, Montreal, May 5, 2006: *The Quality and Appropriateness of Healthcare Interventions*

Healthcare 2006: New research, new priorities, new directions. An ICES Symposium. Toronto, January 23, 2006: *Regionalization in Alberta and the Importance of Health Information.*

Local Health Integration Networks, From Plans to Reality: Better Healthcare Delivery for Ontarians, an *Insight Conference*, November 29, 2005, Toronto, Ontario: *Regionalization in Alberta*

Canadian Society of Transfusion Medicine, Banff, Alberta, April 23, 2005: *The Appropriateness of IVIG Use.*

Local Health Integration Networks. Transforming Healthcare in Ontario, an *Insight Conference*, February 28, 2005, Toronto, Ontario: *Regionalization in Alberta: a model for Ontario?*

20th Annual Emanuel Goldberg Family Lecture, Department of Neurology, University of Rochester, October 8, 2004: *Doing the right thing right: Outcomes research and carotid endarterectomy.*

Department of Community and Preventive Medicine, University of Rochester, October 7, 2004: *Canadian Medicare: Is it a fix for US healthcare?*

12th Annual Cochrane Colloquium, Ottawa, Ontario, October 6, 2004. *Evidence, Administrators and Clinicians: Uneasy Bedfellows.*

Clinical Scholars Program, UCLA Faculty of Medicine, April 17, 2003: *Outcome studies of carotid endarterectomy*

Department of Neurology, Columbia University, New York, April 26, 2002: *Measuring the Effectiveness of Carotid Endarterectomy*

Advances in Stroke Prevention, University of Western Ontario, London, Ontario, February 11, 2002. *Outcome studies in carotid endarterectomy.*

Joe Doupe Memorial Lecture: *From Efficacy to Effectiveness, the Example of Carotid Endarterectomy.* Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, August 24, 2001.

Inaugural address, Class of 2005, University of Manitoba, Winnipeg, Manitoba, August 22, 2001.

Royal College Lecturer, Canadian Congress of Neurological Sciences meeting, Ottawa, June 15, 2000: *Neurological and Neurosurgical Outcomes: Can they be measured and do they matter?*

Invited Speaker, Canadian Congress of Neurological Sciences meeting, Ottawa, June 14, 2000, *Molecular Mechanisms of Neuromuscular Disease: Antibody-mediated Neuropathies*

Invited Speaker, Section of Neurology, University of Manitoba, Winnipeg, March 10, 2000: *Measuring the quality and effectiveness of health care.*

The 27th Allan Bailey Memorial Lecture, University of Saskatchewan, Saskatoon, December 1, 1999: *Measuring the quality and effectiveness of health care*

Invited Speaker, Division of Neurology, University of Saskatchewan, November 30, 1999: *Pathogenesis of Guillain-Barré Syndrome*

Invited Speaker, Festschrift for Dr. Charles F. Bolton, University of Western Ontario, London, Ontario, April 24, 1999: *Measurement of Quality of Health Care: the Example of Carotid Endarterectomy*

Invited Speaker, Immunosuppressive Treatment for Neurologists Course, American Academy of Neurology Meeting, Toronto, April 23, 1999: *Management of the Immune Mediated Neuropathies*

Invited Speaker, Immunosuppressive Treatment for Neurologists Course, American Academy of Neurology Meeting, Minneapolis, May 2, 1998: *Management of the Immune Mediated Neuropathies*

Invited Speaker, Peripheral Neuropathy Course, American Academy of Neurology Meeting, Minneapolis, April 26, 1998: *Pathogenesis and Management of Guillain-Barré Syndrome*

Invited Speaker, Montreal Neurological Institute, McGill University, Montreal, May 23, 1997: *Pathogenesis of Guillain-Barré Syndrome*

Dupont Lecture, Dalhousie University, Halifax, Nova Scotia, May 21, 1997. *The Evolution of Guillain-Barré Syndrome*

Invited Speaker, Division of Neurology, Dalhousie University, Halifax Club, Halifax, Nova Scotia, May 20, 1997. *Recent Advances in Clinical Neurosciences*

Invited Speaker, Peripheral Neuropathy Course, American Academy of Neurology Meeting, San Francisco, March 1996, *Diagnosis and Management of Demyelinating Peripheral Neuropathies*

Invited Lecture: Department of Neurology, Second Teaching Hospital, Hebei Province, Shijiazhuang, People's Republic of China, *Pathogenesis of Guillain-Barré Syndrome*, October 19, 1995

Invited Speaker, World Congress of Electromyography and Clinical Neurophysiology, Kyoto, Japan, October 15-19, 1995, 1. *Conduction Block in Demyelinating Neuropathies*; 2. *Plasma Exchange and Intravenous Immunoglobulin in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy*

Visiting Professor, Department of Neurology, Baylor University College of Medicine, Texas Medical Center, Houston, Texas: *The Evolution of Guillain-Barré Syndrome*, September 7-8, 1995

Invited Speaker, Canadian Bar Association: *Contentious Medical-Legal Issues in Multiple Sclerosis and Stroke*, Calgary, June 6, 1995

Invited Speaker, Peripheral Neuropathy Course, American Academy of Neurology meeting, Washington, DC, April 1994: *Diagnosis and Management of Demyelinating Peripheral Neuropathies*

Invited Speaker, World Congress of Neuromuscular Disease, Kyoto, Japan: *Management of Demyelinating Polyneuropathies*, July 1994

Course Organizer, *Therapeutics in Neurology*, Royal College of Physicians and Surgeons meeting, Vancouver, BC, Sept. 10, 1993

Invited Lecturer, *The Pathophysiology of Human Demyelinating Neuropathies*, at the Institute of Neurology, Queen Square, London, U.K., July 30, 1993

Invited Speaker, Peripheral Neuropathy Course, American Academy of Neurology meeting, New York, April 30, 1993: *Diagnosis and Management of Demyelinating Peripheral Neuropathies*

Invited Speaker, Legal Education Society of Alberta, March 29, 1993: *Neurological Aspects of Medical-Legal Litigation*

Visiting Professor, University of British Columbia, Division of Neurology, December 15-16, 1992: 1. *Management of the Demyelinating Polyneuropathies*; 2. *Pathogenesis of Experimental Allergic Neuritis*

Visiting Professor, Department of Neurology, Wayne State University Medical Center, Detroit, Michigan, November 12-13, 1992; *Management of the Demyelinating Polyneuropathies*

Alberta Heritage Foundation for Medical Research Lecturer, Division of Neurology, University of Alberta, Edmonton, March 25, 1992: *The Demyelinating Neuropathies*

Invited Lecturer, The Nucleus Ambiguous Club of Edmonton, March 24, 1992: *Optic Neuritis*

Invited Lecturer, Symposium on Classification of Guillain-Barré Syndrome, National Institutes of Health, June 27 - 28, 1991

Invited Lecturer, Department of Clinical Neurosciences, University of Calgary, November 16, 1990, *Pathogenesis of Guillain-Barré Syndrome*

Course Co-organizer, *Management of Neuromuscular Disease in the 1990s*, Neuromuscular Course, Niagara-on-the-Lake, September, 1989

Invited Lecturer, International Guillain-Barré Syndrome Symposium, Philadelphia, October, 1988

Invited Lecturer, Canadian Apheresis Society, Chateau Montebello, Quebec, October 1988 : *The Role of Plasmapheresis in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy*

Invited Lecturer, Southern Ontario Neuroscience Association. *The Future of Neuroscience Research in Ontario*, May 1988

Invited Lecturer, *Mechanisms of Demyelination*, American Academy of Neurology Meeting, Cincinnati, Ohio, April 1988

Conference Chair, Peripheral Nerve Study Group Meeting, Lake Couchiching, Ontario, August, 1987

Invited Lecturer, Institute of Neurology, Queen Square, London, England, September 23, 1985: *Guillain-Barré Syndrome and Experimental Allergic Neuritis*

Visiting Professor, Department of Neurology, University of Rochester, Rochester, New York, November 15-16, 1984: *Pathogenesis of the Demyelinating Neuropathies*

Invited Lecturer, Grand Medical Rounds, Winnipeg Health Sciences Centre, September 28, 1984: *The Pathogenesis of Guillain-Barré Polyneuropathy*

Invited Lecturer, University of Manitoba Neuroscience Rounds, September 28, 1984: *Optic Neuritis and Multiple Sclerosis*

Invited Lecturer, Peripheral Neuropathies 1984: Advances and New Approaches, at the Canadian Congress of Neurological Sciences, Edmonton, Alberta, June 1984, 1. *Pathogenesis of Guillain-Barré Syndrome*: Update; 2. *Neuropathies associated with paraproteinemia*

Course Chairman, *Current Concepts of Neuroimmunological Diseases*, Canadian Congress of Neurological Sciences, St. John's, Newfoundland, June 22, 1983

Invited Speaker, Symposium on Guillain-Barré Syndrome, September 20, 1982, Royaumont, France.

Co-Director, International Symposium on Research in Multiple Sclerosis, University Hospital, London, Ontario, May 3-5, 1981

Invited Lecturer, Royal College of Physicians and Surgeons of Canada Meeting, Ottawa, June 1980, Symposium, on Acoustic Neuroma. *Auditory evoked responses in the diagnosis of acoustic neuroma*

RESEARCH FUNDING (as PI unless noted)

1978-80	Medical Research Council	44,000
1978-80	P.S.I. Foundation (with D.W. Paty and G.C. Ebers)	83,385
1979-81	Muscular Dystrophy Association of Canada (with J.J. Gilbert)	85,472

1979-80	Multiple Sclerosis Society (with J.J. Gilbert & A.F. Hahn)	45,000
1981-83	Muscular Dystrophy Association of Canada (with J.J. Gilbert and A.F. Hahn)	106,000
1982-84	National Institutes of Health	25,000
1983-85	Muscular Dystrophy Association of Canada (with J.J. Gilbert & A.F. Hahn)	108,000
1985-87	Muscular Dystrophy Association of Canada (with J.J. Gilbert & A.F. Hahn)	105,000
1985-87	Medical Research Council (with J.J. Gilbert & A.F. Hahn)	91,650
1986-88	Muscular Dystrophy Association of Canada (with P.J. McAlpine & A.F. Hahn)	84,000
1987-89	Medical Research Council (with A. J. Fox, G.C. Ebers & S. J. Karlik)	59,149
1988-91	Muscular Dystrophy Association of Canada (with A. F. Hahn)	175,000
1988-91	Medical Research Council (with A. F. Hahn)	105,000
1990-93	Muscular Dystrophy Association of Canada (with A. F. Hahn, D. A. Sim)	270,750
1991-94	Muscular Dystrophy Association of Canada (with A. F. Hahn)	295,000
1993-95	Miles/Canadian Red Cross Research and Development Fund (with D. W. Zochodne)	80,000
1996-97	Bayer/Canadian Red Cross Research and Development Fund (with D. W. Zochodne)	42,000
1999-2002	Heart and Stroke Foundation of Canada	138,000
1999-2001	Alberta Foundation for Health Research (with G. Sutherland, A. Buchan, W. Becker)	500,000
2000-2002	Canadian Stroke Network	25,500
2000-2003	Canadian Institutes of Health Research (with A. Buchan and W. Ghali)	200,000
2003-2006	Canadian Institutes of Health Research	245,000

	(with W. Ghali, H. Quan, J. Hoch, D. Pi, A. Tinmouth)	
2005-2006	Canadian Patient Safety Institute (Alan Forster, PI)	100,000
2006-2008	Talecris Pharmaceuticals	25,000
2007-10	Canadian Institutes of Health Research (with K. Shojania, A. Forster, D. Emery, E. Wai, K. O'Rourke)	433,000
2011-13	Canadian Institutes of Health Research (A. Laupacis, PI)	198,600
2012-13	Canadian Institutes of Health Research (J Busse, PI)	94,452
2014-16	The GBS/CIDP Foundation of Canada, CSL/Behring Inc and Grifols Inc, for the IGOS Study	42,000

GRADUATE STUDENTS

2014 Peter Podgorny, Department of Clinical Neurosciences, MSc

Ph.D. EXAMINATION COMMITTEES

2007 Nicole Grimm, Department of Medicine, University of Alberta

2005 Justyna Sarna, Department of Neuroscience, University of Calgary

1997 Scott Day, Department of Clinical Neurosciences, University of Calgary

1993 Gordon Boorman, Departments of Physiology and Clinical Neurosciences, University of Calgary.

1988 Didier Flament, Department of Physiology, University of Western Ontario

RESEARCH FELLOWS AND STUDENTS

Current Position

S Magnan 2006 Psychiatrist, Edmonton, Alberta

C Toth 2002-05 Neurologist, Burnaby, BC

J Kennedy 2001-05 University Lecturer, Oxford University

A Hoke, 1997-99 Professor of Neurology, Johns Hopkins University

F Grand'Maison, 1989-90	Neurologist, Montreal, Québec
NJ Witt, 1987-88	Neurologist, Edmonton, Alberta
DW Zochodne, 1985-86	Professor of Neurology, University of Alberta

FORMAL MENTORING

Current Position

Melanie Rock 2016-	Associate Professor of Community Health Sciences, University of Calgary
Tom Stelfox 2016-	Associate Professor of Medicine, University of Calgary
Hude Quan 2015-	Professor of Community Health Sciences, University of Calgary
Jonah Zankl 2015-	BSc student, University of Calgary
Nathan Rider 2013-16	BSc student, University of Calgary
Brenda Hemmelgarn 2012-	Professor of Medicine and Head of the Department of Community Health Sciences, University of Calgary
Dhekra al-Basha 2012-14	PhD student, University of Toronto
Justin Ezekowitz 2006-07	Associate Professor, Division of Cardiology, University of Alberta
Karen Doucette 2004 -07	Associate Professor, Division of Infectious Diseases, University of Alberta
Corinne Schalm 2004-06 -	Director, Corporate Planning, Capital Care Group, Edmonton

TEACHING ADMINISTRATION

1991-2002	Residency Training Committees in Neurology and Neurosurgery(ex officio), Department of Clinical Neurosciences, University of Calgary
-----------	--

1985-87	Post-Graduate Education Committee, Department of Clinical Neurological Sciences, University of Western Ontario
1985-87	Resident Program Coordinator, University Hospital, London, Ontario
1980-83	Chair , Neurosciences and Mind Course (1 st and 2 nd year Medicine), University of Western Ontario, London, Ontario
1977-80	Director of Neurology Residents' Basic Science Course, University of Western Ontario, London, Ontario
1980-83	Undergraduate Medical Education Committee, University of Western Ontario
1979-81	University Hospital Postgraduate Medical Education Committee, London, Ontario

PUBLICATIONS

ARTICLES

1. Feasby, TE. and Brown, WF. (1974). Motor unit size variation in the human extensor digitorum brevis and thenar muscles. *J Neurol Neurosurg Psych* 37:916-926
2. Brown, WF. and Feasby, TE. (1974). Estimates of functional motor axon loss in diabetics. *J Neurol Sci*. 23:275-293
3. Feasby, TE., Kaufmann, JCE. and Ferguson, GG. (1975). Isolated spinal cord arteritis. *Can J Neurol Sci* 2:143-146
4. Hahn, AF., Gilbert, JJ. and Feasby, TE. (1980). Passive transfer of demyelination by experimental allergic neuritis serum. *Acta Neuropath* 49:169-176
5. Feasby, TE., Pullen, AH., and Sears, TA. (1981). A quantitative ultra-structural study of dorsal root regeneration. *J Neurol Sci* 49:363-386
6. Feasby, TE. Bostock, H. and Sears, TA. (1981). Conduction in regenerating dorsal root fibres. *J Neurol Sci* 49:439-454
7. Ebers, GC, Cousin, K, Feasby, TE and Paty, DW (1981). Optic neuritis in familial multiple sclerosis. *Neurology* 31:1138-1141
8. Feasby, TE., Paty, DW., Ebers, GC. and Fox, AJ. (1981). Spinal cord swelling in multiple sclerosis. *Can J Neurol Sci* 8:151-153

9. Dales, S., Ebers, GC., Feasby, TE., and Paty, DW. (1981). Conference Report: International Symposium on Multiple Sclerosis. University of Western Ontario, May 3-5, 1981. *Can J Neurol Sci* 8:333-338
10. Brown, WF., Feasby, TE., Gilbert, JJ., Yates, SK. and Houlden, DA. (1981). Conduction block and denervation in Guillain-Barré polyneuritis. *Trans Am Neurol Assoc* 168-172
11. Vinuela, F., Fox, AJ., Debrun, GM., Feasby, TE., and Ebers, GC. (1982). New perspectives in computed tomography of multiple sclerosis. *Amer J Neuroradiol* 3:277-281
12. Hernandez, D., Vinuela, F., and Feasby, TE. (1981). Recurrent paraplegia with total recovery from spontaneous spinal epidural hematoma, *Ann Neurol* 11:623-624
13. Feasby, TE., Gilbert, JJ. and Hahn, AF. (1982). Passive transfer studies in Guillain-Barré polyneuropathy. *Neurology* 32:1159-1167
14. Lo, R. and Feasby, TE. (1983). Multiple Sclerosis and autoimmune diseases. *Neurology* 33:97-98
15. Hahn, AF., Gilbert, JJ. and Feasby, TE. (1983). Paraparesis following intrathecal chemotherapy. *Neurology* 33:1032-1038
16. Gilbert, JJ., Feasby, TE., and Hahn, AF. (1983). Intraneural injection of lymphocytes in experimental allergic neuritis. *Acta Neuropath* 61:61-64
17. Ebers, GC. and Feasby, TE. (1983). Optic neuritis and multiple sclerosis. *Can J Neurol Sci* 10:79-80
18. Noseworthy, JH., Paty, DW., Feasby, TE., Wonnacott, T. and Ebers, GC. (1983). Multiple sclerosis after age 50. *Neurology* 33:1537-1544
19. Brown, WF. and Feasby, TE. (1984). Conduction block and denervation in Guillain-Barré polyneuropathy. *Brain* 107:219-239
20. Ebers, GC., Feasby, TE., Bass, B. and Vinuela, F. (1984). Multifocal CT enhancement in M.S. *Neurology* 34:341-346
21. Brown, WF., and Feasby, TE. (1984). Sensory evoked potentials in Guillain-Barré polyneuropathy. *J Neurol Neurosurg Psychiat* 47:288-291
22. Feasby, TE., Mazaheri, R., Hahn, AF., Gilbert, JJ. Stiller, CR., and Keown, P. (1984). Circulating lymphocyte subpopulations in experimental allergic neuritis. *J Neuroimmunol* 6:209-214
23. Feasby, TE., Brown, WF., Hahn, AF., and Gilbert, JJ. (1985). The pathological basis of conduction block in human neuropathies. *J Neurol Neurosurg Psychiat* 48:239-244
24. Hahn, AF., Feasby, TE., Gilbert, JJ. (1985). Blood-nerve barrier studies in experimental allergic neuritis. *Acta Neuropathol* 68:101-109
25. The Guillain-Barré Study Group (Feasby, TE) (1985). Plasmapheresis and acute Guillain-Barré Syndrome. *Neurology* 35:1096-1104
26. Stoessl, AJ. Young, GB., Feasby, TE. (1985). Intracerebral haemorrhage and angiographic beading following ingestion of oral catecholamines. *Stroke* 16:734-736

27. Feasby, TE., Gilbert, JJ., Brown, WF., Bolton, CF., Hahn, AF., Koopman, WJ. and Zochodne, DW. (1986). An acute axonal form of Guillain-Barré polyneuropathy. *Brain* 109:1115-1126
28. Feasby, TE., Hahn, AF., Gilbert, JJ. and Lovgren, DL. (1987). Treatment of EAN with prednisolone. *Can J Neurol Sci* 14:46-49
29. Feasby, TE., Gilbert, JJ., Hahn, AF., and Neilson, M. (1987). Complement depletion suppresses Lewis rat experimental allergic neuritis. *Brain Research* 419:97-103
30. Goodridge, A., Feasby, TE., Ebers, GC., Brown, WF., and Rice, G. (1987). Hand wasting due to mid-cervical spinal cord compression. *Can J Neurol Sci* 14:309-311
31. McKhann, GM., Griffin, JW., Cornblath, DR., Mellits, ED., Fisher, RS., Quaskey, SA. and the Guillain-Barré Syndrome Study Group (Feasby, TE) (1988). Plasmapheresis and Guillain-Barré Syndrome; analysis of prognostic factors and the effect of plasmapheresis. *Annals of Neurology* 23:347-353
32. Cornblath, DR., Mellits, ED., Griffin, JW., McKhann, GM., Albers, JW., Miller, RG., Feasby, TE., Quaskey, SA., and the Guillain-Barré Syndrome Study Group (1988). Motor conduction studies in Guillain-Barré Syndrome: description and prognostic value. *Annals of Neurology* 23:354-359
33. Hahn, AF., Feasby, TE., Steele, A., Lovgren, D. and Berry, J. (1988). Demyelination and axonal degeneration in Lewis rat EAN depend on the myelin dosage. *Lab Invest* 59:115-215
34. Feasby, TE., Hahn, AF., Koopman, WJ., Lee, DG. (1990). Central lesions in chronic inflammatory demyelinating polyneuropathy - A MRI Study. *Neurology* 40:476-478
35. Hahn, AF., Brown, WF., Koopman, WJ., Feasby, TE. (1990). X-linked dominant hereditary motor and sensory neuropathy (HMSN). *Brain* 113:1511-1525
36. McAlpine, PJ., Feasby, TE., et al (1990). Localization of a locus for Charcot-Marie-Tooth neuropathy type Ia (CMT1A) to chromosome 17 proximal to 17p13.1. *Genomics* 7:408-415
37. Feasby, TE. (1991). Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies. *J Neurol, Neurosurg, Psychiat* 54:51-54
38. Lee, D. H., Simon, J. H., Szumowski, J., Feasby, TE., Karlik, S. J., Fox, A. J., Pelz, D., M. (1991). Optic neuritis and orbital lesions: lipid-suppressed chemical shift MR imaging. *Radiology* 179:543-546
39. Hahn, AF., Feasby, TE., Wilkie, L., Lovgren, D. (1991). P₂-peptide induced EAN - a model to study axonal degeneration. *Acta Neuropathologica* 82:60-65
40. Cornblath, D., Asbury, A., Albers, J., Feasby, TE., Hahn, A., McLeod, J., Mendell, J., Parry, G., Pollard, J., Thomas, P. (1991). Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). *Neurol* 41:617-618
41. Grand'Maison, F., Feasby, TE., Hahn, AF., Koopman, W. (1992). Recurrent Guillain-Barré Syndrome: clinical and laboratory features. *Brain* 115:1093-1106

42. Feasby, TE., Burton, S., Hahn, AF. (1992). Obstetrical lumbosacral plexus injury. *Muscle and Nerve* 15:937-940
43. Feasby, TE., Hahn, AF., Bolton, CF., Brown, WF., Koopman, WJ. (1992). Detection of hereditary motor sensory neuropathy type I in childhood. *J Neurol, Neurosurg, Psychiat.* 55:895-897
44. Feasby, TE., Hahn, AF., Brown, WF., Bolton, CF., Koopman, WJ. (1993). Severe axonal degeneration in acute Guillain-Barré Syndrome -- evidence of two different mechanisms. *Journal of the Neurological Sciences* 116:185-192
45. Brown, WF., Feasby, TE., Hahn, AF. (1993). Electrophysiological changes in the acute "axonal" form of Guillain-Barré syndrome. *Muscle and Nerve* 16:200-205
46. Tawil, R., Storvick, D., Feasby, TE., Weiffenbach, B., Griggs, RC. (1993): Extreme variability of expression in monozygotic twins with FSH Muscular Dystrophy. *Neurology* 43:345-348
47. Guillain-Barré Syndrome Steroid Trial Group (Feasby, TE) (1993). Double-masked trial of intravenous methylprednisolone in Guillain-Barré syndrome. *Lancet* 341:586-590
48. Hahn, AF., Feasby, TE., Wilkie, L., Lovgren, D. (1993): Anti-galactocerebroside antibody increases demyelination in adoptive transfer experimental allergic neuritis. *Muscle and Nerve* 16: 1174-1180
49. Tawil, R., Storvick, D., Weiffenbach, B., Altherr, M., Feasby, T.E., Griggs, R.C. (1993). Chromosome 4q DNA rearrangement in one member of a pair of monozygotic twins discordant for FSH muscular dystrophy. *Human Mutation* 2:492-494
50. Hahn, AF., Feasby, TE., Lovgren, D., Wilkie, L. (1994). Adoptive transfer EAN in the immune suppressed host. *Acta Neuropathologica*, 86: 596-601
51. Feasby, TE., Hahn, A.F., Lovgren, D.S., Wilkie, L. (1994). Lewis rat EAN is suppressed by the 21-aminosteroid tirilazad mesylate (U-74006F). *Neuropathology and Applied Neurobiology* 20: 384-391
52. Feasby, TE. (1994) "Axonal" Guillain-Barré Syndrome. *Muscle and Nerve* 17: 678-679
53. Peripheral Nerve Society, (Feasby, TE.) (1995). Diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society. *Ann Neurol.* 38: 478-482
54. Feasby, TE. (1996). Axonal CIDP: a premature concept? *Muscle and Nerve* 19:372-374
55. Hahn, AF., Bolton, C.F., Pillay, N., Chalk, C., Benstead, T., Bril, V., Shumak, S., Vandervoort, M., Feasby, TE. (1996). Plasma exchange therapy in chronic inflammatory demyelinating polyneuropathy (CIDP): a double-blind, sham-controlled, cross-over study. *Brain* 119: 1055-1066
56. Hahn, A.F., Bolton, C.F., Zochodne, D., Chalk, C., Feasby, TE. (1996). Intravenous immunoglobulin (IVIg) treatment in Chronic Inflammatory Demyelinating Polyneuropathy: A double-blind placebo-controlled cross-over study. *Brain* 119: 1067-1077
57. The RANTTAS Investigators (Feasby, TE.) (1996). A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). *Stroke* 27: 1453-58

58. Moulin, D.E., Hagen, N., Feasby, TE., Amireh, R., Hahn, A.F. (1997). Pain in Guillain Barré Syndrome. *Neurology* 48:328-331
59. PSGBS Study Group (Feasby, TE.) (1997). Randomized trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain-Barré Syndrome. *The Lancet* 349:225-230
60. Johnston, KC, Li, J, Lyden, R, Hanson, S, Feasby, TE, Adams, R, Faught, R, Haley, EC (1998). Medical and neurological complications of ischemic stroke: experience from the RANTTAS Trial. *Stroke* 29:447-453
61. Feasby, TE and Hughes, RAC. (1998). *Campylobacter Jejuni*, Anti-ganglioside antibodies and Guillain-Barré Syndrome. *Neurology* 51:340-342
62. Hadden, R, Cornblath, D, Hughes, R et al and the Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (Feasby, TE) (1998) Electrophysiological classification of Guillain-Barré Syndrome: clinical associations and outcome. *Annals of Neurology* 44:780-788.
63. Holloway, RG, Feasby, TE. (1999) To test or not to test? That is the question. *Neurology*, 53:1905-1907.
64. Buchan, AM, Barber, PA, Newcommon, N, Karbalai, H, Demchuk, A.M, Hoyte, K.M, Klein, G.M, Feasby, TE. (2000). Effectiveness of t-PA in acute ischaemic stroke: outcome relates to appropriateness. *Neurology*, 54:679-684.
65. Buchan, AM and Feasby, TE. (2000). Stroke thrombolysis: Is tissue plasminogen activator a defibrillator for the brain? *Canadian Medical Association Journal*, 162:47-48.
66. Ashworth, NL, Zochodne, DW, Hahn, AF, Pillay, N, Chalk, C, Benstead, T, Bril, V, Feasby, TE, Bolton, CF. (2000) Impact of plasma exchange on indices of demyelination in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) *Muscle and Nerve*, 23:206-210.
67. Fritzlner, MJ, Kerfoot, SM, Feasby, TE, Zochodne, DW, Westendorf, JM, Dalmau, JO, Chan, EKL.(2000) Autoantibodies from patients with idiopathic ataxia bind to M-phase phosphoprotein-1 (MPP1). *J. Invest Med*, 48:28-39.
68. Federico, P, Zochodne, DW, Hahn, AF, Brown, WF, Feasby, TE. (2000) Multifocal motor neuropathy improved by IVIG: Double-blind placebo-controlled cross-over study. *Neurology*, 55:1249-1255.
69. Feasby, TE. (2000) Endarterectomy for asymptomatic carotid stenosis in the real world. *Can J Neurol Sci*, 27:95-96.
70. Hill, MD, Barber, PA, Takahashi, J, Demchuk, AM, Feasby, TE, Buchan, AM. (2000) Anaphylactoid reactions and angioedema during rtPA treatment of acute ischemic stroke. *Can Med Assoc J*, 162:1281-84.
71. Feasby, TE, Quan, H, Ghali, WA. (2001) Geographic variation in the rate of carotid endarterectomy in Canada. *Stroke* 32:2417-2422.
72. Feasby, TE, Hartung, H-P. (2001) Drain the roots: a new treatment for Guillain-Barré Syndrome? *Neurology*, 57:753-754.

73. Feasby, TE, Quan, H, Ghali, WA. (2002) Hospital and surgeon determinants of outcome for carotid endarterectomy. *Archives of Neurology*, 59:1877-1881.
74. Feasby, TE, Quan, H, Ghali, WA. (2002) Provincial carotid endarterectomy outcomes. *Canadian Journal of Neurological Sciences*, 30:333-336.
75. Feasby, TE. (2003) How appropriate is carotid endarterectomy? *Stroke* 34:1471-2.
76. Findlay, JM, Marchak, BE, Pelz, DM, Feasby, TE. (2004) Carotid endarterectomy: A review. *Canadian Journal of Neurological Sciences*, 31:22-36.
77. Kennedy, J, Quan, H, Ghali, WA, Feasby, TE. (2004) Importance of the imaging modality in decision-making about carotid endarterectomy. *Neurology* 62:901-904.
78. Hill, MD, Foss, MM, Tu, JV, Feasby, TE. (2004) Factors influencing the decision to proceed to carotid endarterectomy. *Neurology* 62:803-805.
79. Feasby, TE, Findlay, JM (2004) CT angiography for the assessment of carotid stenosis. *Neurology*, 63:412-413.
80. Kennedy, J, Quan, H, Ghali, WA, Feasby, TE. (2004) Developing an audit tool for assessing the appropriateness of carotid endarterectomy. *BMC*, 4:17.
81. Kennedy, J, Quan, H, Ghali, WA, Feasby, TE. (2004) Variations in rates of appropriate and inappropriate carotid endarterectomy for stroke prevention in 4 Canadian provinces. *CMAJ* 171(5): 455-9.
82. Hill, MD, Shrive, F, Kennedy, J, Feasby, TE, Ghali, WA. (2005) Simultaneous carotid endarterectomy and coronary artery bypass surgery in Canada. *Neurology* 64:1435-1437.
83. Toth, C, McNeil, S, Feasby, TE. (2005) CNS injuries in sport and recreation. *Sports Medicine* 35:685-715.
84. Toth, C, McNeil, S, Feasby, TE. (2005) PNS injuries in sport and recreation. *Sports Medicine* 35:717-738.
85. Quan, H, Sundararajan, V, Halfon, P, Fong, A, Burnand, B, Luthi, J-C, Saunders, LD, Beck, CA, Feasby, TE, Ghali, WA. (2005) Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data. *Medical Care* 43:1130-1139.
86. Kennedy, J, Quan, H, Buchan, AM, Ghali, WA, Feasby, TE. (2005) Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. *Stroke*, 36:2072-2076.
87. Chaturvedi, S, Bruno, A, Feasby, TE, Holloway, R, Benavente, O, Cohen, SN, Cote, R, Hess, D, Saver, J, Spence, JD, Stern, B, Wilterdink, J. (2005) Carotid endarterectomy--An evidence-based review: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 65:794-801.
88. Feasby, TE, Gerdes, C. (2006) Pay-for-performance – Can it work in Canada? *Healthcare Papers*, 6:47-50.
89. Feasby, TE. (2006) Is the Canadian Healthcare System Better for Neurological Care? *Neurology*, 67:744-747.

90. Feasby, TE, Barnett, HJM. (2007) Improving the appropriateness of carotid endarterectomy. *Neurology*, 68:172-173.
91. Robinson, P, Anderson, D, Brouwers, M, Feasby TE, Hume, H. (2007) Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. *Transfusion Medicine Reviews*, 21 (Suppl 1):S3-S8.
92. Feasby, TE, Banwell, B, Benstead, T, Brill, V, Brouwers, M, Freedman, M, Hahn, A, Hume, H, Freedman, J, Pi, D, Wadsworth, L. (2007) Guidelines on the use of intravenous immune globulin for neurologic conditions. *Transfusion Medicine Reviews*, 21 (Suppl 1):S57-S107.
93. Feasby, TE, Kennedy, J, Quan, H, Girard, L, Ghali, WA (2007) Can randomized controlled trial results for carotid endarterectomy be replicated in the real world? *Archives of Neurology* 64:1496-1500.
94. Hauck, L, White, C, Zochodne, D, Feasby, TE, Hill, MD (2008) Incidence of Guillain-Barré Syndrome in Alberta, Canada; an administrative data study. *Journal of Neurology, Neurosurgery and Psychiatry* 79:318-320.
95. Forster, AJ, LaBranche, R, McKim, R, Faught, W, Feasby, TE, Janes-Kelley, S, Shojania, K, van Walraven, C. (2008) Automated patient assessments following outpatient surgery using an interactive voice response system. *American Journal of Managed Care*, 14:429-436.
96. Emery, DJ, K, Forster, AJ, Shojania, K, Magnan, S, Tubman, M, Feasby, TE. (2009) Management of MRI Wait Lists in Canada. *Healthcare Policy.*, 4:76-86.
97. Forster, AJ, Boyle, L, Shojania, K, Feasby, TE, van Walraven, C. (2009) Identifying patients with post-discharge care problems using an interactive voice response system. *Journal of General Internal Medicine*, 24:520-525.
98. Girard, L, Feasby, TE, Eliasziw, M, Quan, H, Kennedy, Barnett, HJM, Ghali, WA. (2009) Complication rates after left vs. right-sided carotid endarterectomy. *Circulation: Cardiovascular Quality and Outcomes*, 2:642-7.
99. Feasby, TE. (2009) Non-invasive carotid artery imaging. *Annals of Internal Medicine, ACP Journal Club*, 151:4.
100. So, L, Beck, C, Brien, S, Kennedy, J, Feasby, TE, Ghali, WA, Quan, H. (2010) Chart documentation quality and its relationship to the validity of administrative data discharge records. *Health Informatics Journal*, 2:101-113.
101. Flemons, WW, Feasby, TE, Wright, B. (2011) Building a safety and quality culture in healthcare: where it starts. *Healthcare Papers*, 11:41-47.
102. Laupacis, A, Lillie, E, Dueck, A, Straus, S, Perrier, L, Burton, J, Aviv, R, Thorpe, K, Feasby, TE, Spears, J. (2011) Systematic review of the association between chronic cerebral spinal venous insufficiency (CCSVI) and multiple sclerosis. *CMAJ* 2011. DOI 10:1503/cmaj.11074 .
103. Feasby, TE, Quan, H, Tubman, M, Pi, D, So, L, Tinmouth, A, Ghali, WA (2012) Utilization controls and the appropriateness of intravenous immunoglobulin. *Open Medicine* 2012;6(1)e30 <http://www.openmedicine.ca/article/view/480>

104. Emery, D, Forster, A, Shojania, K, Mojaverian, N, Feasby, TE. (2013) Overuse of MRI Scanning. *JAMA-Internal Medicine*, published Online, March 25, 2013, and in print 2013;173:823-825.
105. Anne Abbott, Mark Adelman, Andrei Alexandrov, P Barber, Henry Barnett, Jonathan Beard, Peter Bell, Martin Björck, David Blacker, PD Leo Bonati, Martin Brown, Clifford Buckley, Richard Cambria, John Castaldo, Anthony Comerota, E. Sander Connolly, Jr, Ronald Dalman, Alun Davies, Hans-Henning Eckstein, Rishad Faruqi, Thomas E. Feasby, Gustav Fraedrich, Peter Gloviczki, Graeme Hankey, Robert Harbaugh, Eitan Heldenberg, Michael Hennerici, Michael Hill, Timothy Kleinig, Dimitri Mikhailidis, Wesley Moore, A Naylor, Andrew Nicolaides, Kosmas Paraskevas, David Pelz, James Prichard, Grant Purdie, Jean-Baptiste Ricco, Peter Ringleb, Thomas Riles, Peter Rothwell, Peter Sandercock, Henrik Sillesen, J. David Spence, Francesco Spinelli, Jonathan Sturm, Aaron Tan, Ankur Thapar, Frank Veith, Tissa Wijeratne, and Wei Zhou (2013) Why calls for more routine carotid stenting are currently inappropriate: An international, multispecialty, expert review and position statement. *Stroke*, March 19, 2013, <http://stroke.ahajournals.org/content/early/2013/03/19/STROKEAHA.111.000261.full.pdf?ijkey=Y7M4Vut6l0FU8Bq&keytype=ref>
106. Busse, JW, Riva, JJ, Rampersaud, R, Guyatt, GH, Goytan, MJ, Feasby, TE, Reed, M, You, J. (2014) 57(2)E25-E30 Imaging Practices for Spine-Related Complaints Referred for Surgical Assessment: A Survey of Canadian Spine Surgeons. *Canadian Journal of Surgery*, <http://canisurg.ca/vol57-issue2/57-2-e25/>
107. Podgorny, P, Suchowersky, O, Romanchuk, K, Feasby, TE. (2016) Evidence for small fiber neuropathy in early Parkinson's Disease. *Parkinsonism and Related Disorders*, 28C:94-99.
108. Yavin, D, Casha, S, Wiebe, S, Feasby, TE, Atta, C, Isaacs, A, Holroyd-Leduc, J, Hurlbert, J, Quan, H, Nataraj, A, Sutherland, G, Jette, N. (2016) Lumber fusion for degenerative disease: a systematic review and meta-analysis. *Neurosurgery*, 80(5):701-715.
109. Yavin, D, Casha, S, Wiebe, S, Feasby, TE, Holroyd-Leduc, J, Hurlbert, J, Quan, H, Nataraj, A, Sutherland, G, Bartleson, J, Christie, S, Davenport, J, Findlay, T, Fleetwood, I, Furlan, A, Gallagher, C, Mukhida, K, Ouellet, J, O'Toole, J, Reitman, C, Williamson, O, Dhaliwal, P, du Plessis, S, Carragee, E, Jette, N. Lumbar Spinal Fusion, a RAND/UCLA Appropriateness Study. Submitted to *JAMA*, 2017.
110. Jacobs, BC, van den Berg, B, Verboon, C, Chavada, G, Cornblath, DR, Gorson, KC, Harbo, T, Hartung, HP, Hughes, RAC, Kusunoki, S, van Doorn, PA, Willisonk HJ, Feasby, TE and the IGOS Consortium (2017) International Guillain-Barré Syndrome Outcome Study (IGOS):Protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome *Journal of the Peripheral Nervous System*, published online, 8 June 2017, DOI: 10.1111/jns.12209.

CHAPTERS

1. Feasby, TE. (1992). Inflammatory - Demyelinating Polyneuropathies. In *Neurologic Clinics*. Dyck, P.J., ed. W.B. Saunders Co. 10:651-670
2. Feasby, TE. (1993). Acute Guillain-Barré Syndrome, in *Current Therapy in Neurologic Disease*, R.T Johnson and JG Griffin, ed. B.C. Decker, Philadelphia. pp 347-349
3. Feasby, TE. (1996). Disorders of the Peripheral Nervous System, chapter 452, pp 2441-2451 in *Textbook of Internal Medicine*, third edition, edited by William N. Kelly, Lippincott-Raven, Philadelphia
4. Feasby, TE. (1996). Pathophysiology of Human Demyelinating Neuropathies, in *The Neurobiology of Disease*, pp 86-94, edited by Bostock, Kirkwood & Pullen, Cambridge University Press
5. Feasby, TE. (1996). Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pp. 884-886 in *Recent Advances in Clinical Neurophysiology* edited by J. Kimura and H. Shibasaki. Elsevier Science B.V.
6. Feasby, TE. (1996). Conduction Block in Demyelinating Neuropathies, pp 887-889 in *Recent Advances in Clinical Neurophysiology* edited by J. Kimura and H. Shibasaki. Elsevier Science B.V.
7. Hoke, Ahmet and Feasby, TE. (2000) Disorders of the Peripheral Nervous System, pp 2975-2987, in *Kelly's Textbook of Internal Medicine*, fourth edition, edited by H. David Humes, Lippincott-Raven, Philadelphia.
8. Feasby, TE. (2001) The Appropriateness and Effectiveness of Stroke Prevention, pp. 295-312, in *Stroke Prevention*, Norris, J, Hachinski, V, eds, Oxford University Press.
9. Hill, MD and Feasby, TE. (2002) Principles of Clinical Neuro-Epidemiology, pp 118-126, in *Diseases of the Nervous System – Clinical Neurosciences and Therapeutic Principles*, 3rd edition, Asbury, AK, McKhann, GM, McDonald, WI, Goadsby, PJ, McArthur, JC eds, Cambridge University Press.
10. Feasby, TE. (2016) GBS100. Axonal Guillain-Barré Syndrome, in *GBS 100, Celebrating a century of progress in Guillain-Barre Syndrome*, HJ Willison and JA Goodfellow, eds, Peripheral Nerve Society, ISBN:978-0-9975103-0-0.

NON-PEER REVIEWED PUBLICATIONS

1. O'Brien, RA and Feasby, TE (1988) How to recognize Guillain-Barré Syndrome. *Diagnosis* 199-201.
2. Roifman, C, Balter, M, Blanchette, V, Cardella, C, Feasby, TE., Lipton, J, Mazer, B, McGeer, A, Ross, H, Rubin, L, Sander, D, Stephenson, M. (1997). Present and Future Uses of Immune Globulin (IVIg): A Canadian Multidisciplinary Consensus-Building Initiative. McLean Hunter Publishers
3. Feasby, TE. (1998). U.S. health system too sick for us to adopt. *Calgary Herald*, Op-Ed, July 4, 1998

4. Becker, WJ, Feasby, TE. (2000) Chinook arch over Calgary. *Neuroimages*, in *Neurology* 54:378.
5. Feasby, TE (2002) Stick to proven treatments. *The Globe and Mail*, Op-Ed, September 24, 2002.
6. Feasby, TE (2002) Getting better results. *The Ottawa Citizen*, Op-Ed, October 31, 2002
7. Feasby, TE (2006) Troubled times at the CMAJ. *University of Alberta Health Sciences Journal*, 3:4.
8. Feasby, TE (2007) A cure for what ails family practice. *Calgary Herald*, Op-Ed, October 7, 2007.
9. Feasby, TE (2008) Medical schools are working hard to help cure the doctor shortage. *The Globe and Mail*, Op-Ed, January 28, 2008, <http://www.theglobeandmail.com/servlet/story/RTGAM.20080129.wcomment29/BNStory/specialComment/?page=rss&id=RTGAM.20080129.wcomment29>
10. Feasby, TE, Noseworthy, TN (2009) Fluoride is a public good. *Calgary Herald*, Op-Ed, April 6, 2009
11. Feasby, TE. (2010) Wrong to tarnish health committee's work. *The Edmonton Journal*, June 18, 2010, <http://www2.canada.com/edmontonjournal/news/letters/story.html?id=b1342b14-df51-49e0-9d3d-3fb79f84d6d7>
12. Feasby, TE, Power, C (2012) John W. Griffin (1942-2011), In Memoriam. *Can J Neurol Sci*.39:103.
13. Feasby, TE (2012) A new perspective: the health-care glass is not half empty. *Calgary Herald*, Op-Ed, March 11, 2012 http://www.calgaryherald.com/story_print.html?id=6284288&sponsor
14. Four systematic reviews of the evidence regarding chronic cerebral spinal venous insufficiency (CCSVI) and multiple sclerosis for the CIHR Expert Panel, 2011-12
From the Canadian Chronic Cerebrospinal Venous Insufficiency Systematic Review Group
Andreas Laupacis, Erin Lillie, Richard Aviv, Andrew Dueck, Jodi Burton, Laure Perrier, Sharon Straus, Tom Feasby, Kevin Thorpe
15. Feasby, TE, Feasby, JT. Lives Lived, a memoir of Donald Graham Erskine. *Globe and Mail*, March 27, 2017. <http://www.theglobeandmail.com/life/facts-and-arguments/lives-lived-donald-erskine-94/article34431301/>
16. Interview on CBC 1 radio Calgary about the Order of Canada, January 9, 2018. <http://www.cbc.ca/listen/shows/the-homestretch>

LETTERS

1. Feasby, TE., Hahn, AF., Gilbert, JJ. (1983). Neurotoxicity of bacteriostatic water. *New Eng J Med* 308:967
2. Feasby, TE. (1984). Plasmapheresis in neurologic disease. *Arch Neurol* 41:915

3. Feasby, TE., and Brown, WF. (1985). Conduction block in early Guillain-Barré Syndrome. *The Lancet* 332
4. Feasby, TE., et al (1987). Acute "Axonal" Guillain-Barré polyneuropathy. *Neurology* 37:357
5. Feasby, TE. (1996). Editorials in Scientific Publications. *Neurology* 46:883
6. Moulin, DE, Hahn, A, Hagen, N, Feasby, TE. (1998). Pain and opioid analgesia in Guillain-Barré Syndrome. *Neurology* 51:924
7. Buchan, AM and Feasby, TE (2000) Treating stroke. *Can Med Assoc J.* 162:1273-74.
8. Holloway, RG and Feasby, TE (2000) Testing for serum IgM binding to GM1 ganglioside in clinical practice. *Neurology* 54:2353-54.
9. Hill, MD, Barber, PA, Takahashi, J, Demchuk, AM, Feasby, TE, Buchan, AM. (2000) Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke. *Can Med Assoc J.* 163:388-9.
10. Feasby, TE. (2000) The alphabetization of journal articles. *Can J Neurol Sci* 27:354.
11. Federico, P, Zochodne, DW, Feasby, TE (2001) IVIG treatment in multifocal motor neuropathy. *Neurology* 56:1608.
12. Ghali, WA, Quan, H, Feasby, TE. (2001) *Helicobacter pylori* and cerebrovascular disease. *Stroke* 32:1936.
13. Buchan, AM, Feasby, TE. (2002) Treating Stroke. *Can Med Assoc J* 162(9):1273.
14. Feasby, TE, Kennedy, J, Quan, H, Ghali, WA. (2002). Outcomes of carotid endarterectomy performed by vascular surgeons or neurosurgeons, *Stroke* 33:1458.
15. Feasby, TE, Quan, H, Ghali, WA.(2004) Carotid endarterectomy: Turning up the volume?. *Archives of Neurology* 61:296-7.
16. Kennedy, J, Quan, H, Ghali, WA, Feasby, TE. (2004) Importance of the imaging modality in decision-making about carotid endarterectomy. *Neurology*, 63:1340-1341.
17. Feasby, TE. (2007) Is the Canadian healthcare system better for neurologic care? *Neurology* 68:1870-1871.
18. Feasby, TE, Barnett, HJM (2007) Improving the appropriateness of carotid endarterectomy. *Neurology* 68:172-3.
19. Emery, DJ, Feasby, TE. (2013) Overuse of MRI Scanning. *JAMA Internal Med.*, 173, 21.

20. Busse JW, Rampersaud R, White LW, Feasby TE. Recommendations for management of low-back pain misleading. *CMAJ*. 2014;186(9)

ABSTRACTS

1. Feasby, T. E., and Brown, W.F. (1973). A quantitative study of the late thenar response. Presented at the Eighth International Congress of Electroencephalography and Clinical Neurophysiology, Marseilles, France, September
2. Feasby, T.E., and Brown, W.F. (1973). An electrophysiological assessment of the degree of axonal degeneration in diabetic neuropathy. Presented at the Tenth World Congress of Neurology, Barcelona, Spain. September
3. Feasby, T. E., Brown, W.F., and Gilbert, J.J. (1974). Reversible conduction block in human neuropathies. *Can J Neurol Sci* 1:269
4. Brown, W.F., Feasby, T.E., Gilbert, J.J. (1974). An electrophysiological and pathological study of porphyric neuropathy. *Can J Neurol Sci* 1:257
5. Brown, W.F., Feasby, T.E., and Gilbert, J.J. (1975). Reversible conduction block in peripheral nerve. Presented at the Fifth International Congress of Electromyography, Rochester, Minnesota, September
6. Bostock, H., Feasby, T.E., and Sears, T.A. (1977). Continuous conduction in regenerating myelinated nerve fibres. *J Physiol* 269:88-89
7. Feasby, T.E., Pullen, A.H., and Sears, T.A. (1978). Dorsal root regeneration. *Can J Neurol Sci* 5:342
8. Hahn, A.F., Feasby, T.E. and Gilbert, J.J. (1979). Passive transfer of demyelinating activity in experimental allergic neuritis. *Can J Neurol Sci* 6:380
9. Feasby, T.E., Hahn, A.F., and Gilbert, J.J. (1980). Passive transfer of demyelinating activity in Guillain-Barré polyneuropathy. *Neurology* 30:363
10. Feasby, T.E., Paty, D.W., Ebers, G.C., and Fox, A.J. (1980). Spinal cord swelling in multiple sclerosis. *Can J Neurol Sci* 7:324
11. Hahn, A.F., Feasby, T.E. and Gilbert, J.J. (1980). Passive transfer of demyelinating activity in experimental allergic neuritis and Guillain-Barré polyneuropathy. *Can J Neurol Sci* 7:116
12. Vinuela, F., Fox, A.J., Debrun, G., Ebers, G., Feasby, T.E. (1981). New perspectives in computed tomography of multiple sclerosis. Presented at the American Society of neuroradiology Meeting, Chicago, Illinois
13. Brown, W.F., Feasby, T.E., Yates, S.K. (1981). Conduction block and denervation in Guillain-Barré Polyneuritis. *Ann Neurol* 10:86-87

14. Ebers, G.C., Vinuela, F., Feasby, T.E., Paty, D.W. (1981). Multifocal CT enhancement in multiple sclerosis. *Can J Neurol Sci* 8:190
15. Hahn, A.F., Feasby, T.E., Gilbert, J.J. (1982). Blood-nerve barrier in experimental allergic neuritis. *Neurology* 32:154A
16. Hahn, A.F., Gilbert, J.J., Feasby, T.E. (1982). Paraparesis following intrathecal chemotherapy. *Can J Neurol Sci* 9:289
17. Feasby, T.E., Ebers, G.C. (1982). Risk of multiple sclerosis in isolated optic neuritis. *Can J Neurol Sci* 9:269
18. Yates, S.K., Brown, W.F., Feasby, T.E. (1982). Photic evoked blink reflex in optic neuritis, Vth International Congress of Neuromuscular Diseases, Marseille, September 12-17
19. Brown, W.F., Feasby, T.E. (1984). Conduction block and denervation in Guillain-Barré polyneuropathy. *Brain* 107:219-239
20. Brown, W.F., Davis, M., and Feasby, T.E. (1982). The localization conduction abnormalities in Guillain-Barré polyneuritis by somatosensory evoked potential techniques. Vth International Congress on Neuromuscular Diseases, Marseille, September 12-17
21. Feasby, T.E., Hahn, A.F., and Gilbert, J.J. (1982). Blood-nerve barrier studies in experimental allergic neuritis. Vth International Congress on Neuromuscular Disease, Marseille, September 12-17
22. Ebers, G.C., Vinuela, F., and Feasby, T.E. (1982). Multifocal computed tomographic enhancement in multiple sclerosis. *Ann Neurol* 12:91-92
23. Feasby, T.E., Hahn, A.F., Gilbert, J.J. and Brown, W.F. (1983). Pathological basis of conduction block in human neuropathies. American Neurol. Assoc., New Orleans, October 2-5, *Ann Neurol* 14:121, 1983
24. Feasby, T.E., Hahn, A.F. and Brown, W.F. (1983). Long-term plasmapheresis in chronic progressive demyelinating polyneuropathy. American Neurol. Assoc., New Orleans, October 2-5, *Ann Neurol* 14:122, 1983
25. Mazaheri, R., Feasby, T.E., Stiller, C.R., Yang, J., Gilbert, J.J., and Hahn, A.F. (1983). Immunoregulatory T-lymphocyte subsets in experimental allergic neuritis (EAN). Presented at the British Society for Immunology
26. Moulin, D.E., Feasby, T.E., and Ebers, G.C. (1984). The predictive value of evoked potentials in "Possible" multiple sclerosis. *Neurol* 34 (Suppl. 1): 78
27. Hahn, A.F., Feasby, T.E. and Gilbert, J.J. (1984). Blood-nerve barrier studies in experimental allergic neuritis. *J Neuropath Exp Neurol* 43:302
28. Goodridge, A.E., Feasby, T.E., Bolton, C.F., Ebers, G.C., Brown, W.F. (1984). Hand wasting in cervical spondylotic myelopathy. *Can J Neurol Sci* 11:342-343

29. Zochodne, D.W., Feasby, T.E., Brown, W.F., Gilbert, J.J., Koopman, W.J., Hahn, A.F. (1985). Inexcitable motor nerves in Guillain-Barré polyneuropathy. *Can J Neurol Sci* 12:205
30. Feasby, T.E., Gilbert, J.J., Hahn, A.F., Neilson, M. (1985). Complement depletion suppresses Lewis rat EAN. *Can J Neurol Sci* 12:205
31. Rae-Grant, A.D., Feasby, T.E., Brown, W.F., Gilbert, J.J., and Hahn, A.F. (1986). A reversible demyelinating polyneuropathy associated with cancer. *Neurol* 36(suppl 1): 81
32. Feasby, T.E., Hahn, A.F. and Lovgren, D. (1986). Treatment of experimental allergic neuritis by anti-T-cell monoclonal antibodies. *Neurology* 36 (suppl 1): 255
33. Feasby, T.E., Gilbert, J.J., Hahn, A.F., and Calarco, A. (1986). Identification of lymphocytes in EAN lesions by monoclonal antibodies. VI International Congress on Neuromuscular Diseases, Los Angeles, California
34. Hahn, A.F., Feasby, T.E., Koopman, W.J., Mallot, D., Bolton, C.F. and Brown, W.F. (1986). Hereditary neuropathy with liability to pressure palsies (HNPP). VI International Congress on Neuromuscular Diseases, Los Angeles, California
35. Feasby, T.E., Hahn, A.F., Koopman, W.J., McAlpine, P.J., Wong, P., and Lewis, M. (1986). Gene mapping studies of hereditary motor-sensory neuropathy Type I mutations. VI International Congress on Neuromuscular Diseases. Los Angeles, California
36. Feasby, T.E., Gilbert, J.J., and Hahn, A.F. (1986). The effect of complement depletion on Lewis rat EAN. Second Scientific meeting of the Peripheral Neuropathy Association of America. Hilton Head, South Carolina
37. Feasby, T.E., Hahn, A.F., Gilbert, J.J., Brown, W.F., Bolton, C.F., and Koopman, W.J. (1987). Severe acute axonal degeneration in Guillain-Barré syndrome. American Academy of Neurology, New York
38. Hahn, A.F., Feasby, T.E., and Gilbert, J.J. (1987). Axonal degeneration in experimental allergic neuritis (EAN) is related to the immunizing dose of myelin. American Academy of Neurology, New York
39. Feasby, T.E., Ebers, G.C., Fox, A.J., and Karlik, S. (1987). Predictive tests in isolated optic neuritis. XXIIInd Canadian Congress of Neurological Sciences. Vancouver, British Columbia
40. Feasby, T.E., Hahn, A.F., Brown, W.F., Bolton, C.F., and Gilbert, J.J. (1988) Two types of axonal degeneration in acute Guillain-Barré syndrome, European Neurological Society, Nice, France
41. Hahn, A.F., Feasby, T.E., Brown, W.F., and Ebers, G. (1988). Nerve biopsy findings in X-linked dominant inherited motor sensory neuropathy. European Neurological Society, Nice, France
42. Hahn, A.F., Feasby, T.E. (1989). Metronidazole Neuropathy - A sensory neuronopathy. American Academy of Neurology

43. Feasby, T.E., Hahn, A.F., Koopman, W.J., Lee, D.G. (1989). Is there CNS demyelination in chronic inflammatory demyelinating polyneuropathy? XXIVth Meeting of Canadian Congress of Neurological Sciences, Ottawa
44. Graffagnino, C., Feasby, T.E. (1989). Does temporal artery biopsy help in the management of giant cell arteritis? XXIVth Meeting of Canadian Congress of Neurological Sciences, Ottawa
45. McAlpine, P., Feasby, T.E., Hahn, A.F., Lewis, M., et al. (1989). Mapping Mutations Causing Autosomal Dominant Charcot-Marie Tooth Disease. Presented at Human Genome I, San Diego
46. Feasby, T.E., Hahn, A.F., Lovgren, D.S., Wilkie, L. (1990). Axonal degeneration and demyelination in peptide-induced experimental allergic neuritis. Presented at the American Academy of Neurology Meeting, Miami Beach
47. Hahn, A.F., Feasby, T.E., Wilkie, L., Lovgren, D.S. (1990). Dose-dependent demyelination and axonal degeneration in passive cell-transfer EAN. Presented at the American Academy of Neurology Meeting, Miami Beach
48. Hahn, A.F., Feasby, T.E., Lovgren, D.S., Wilkie, L. (1990). Axonal degeneration and demyelination in peptide-induced experimental neuritis. Presented at the Peripheral Neuropathy Association Meeting, Oxford, England
49. Cornblath, D.R., Albers, J.W., Asbury, A.K., Feasby, T.E., Hahn, A.F., McLeod, J.G., Mendell, J.R., Parry, G.J., Pollard, J.D., Thomas, P.K. (1990). Chronic inflammatory demyelinating polyneuropathy (CIDP): Proposed criteria for diagnosis. Presented at the Peripheral Neuropathy Association Meeting, Oxford, England
50. Grand'Maison, F., Feasby, T.E., Hahn, A.F., Koopman, W.J. (1990). Recurrent Guillain-Barré Syndrome: Clinical and laboratory features. Presented at the Peripheral Neuropathy Association Meeting, Oxford, England
51. Feasby, T.E., Hahn, A.F., Koopman, W.J., Bolton, C.F., Brown, W.F. (1990). Detection of HMSN I in Children. Presented at the World Congress of Neuromuscular Diseases. Munich
52. Hahn, A.F., Feasby, T.E., Wilkie, L., Lovgren, D.S., David (1991). Sp₂₆-sensitized T lymphocytes produce demyelination after intraneural adoptive transfer. Presented at the 43rd Annual Meeting of the American Academy of Neurology, Boston, Massachusetts
53. Hahn, A.F., Feasby, T.E. (1992). Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind placebo-controlled crossover study. Presented at the American Neurological Association Meeting, Toronto
54. Feasby, T.E., Hahn, A.F., Wilkie, L., Lovgren, D. (1993). Lewis rat experimental allergic neuritis is suppressed by U-74006F. Presented at the American Academy of Neurology Meeting, New York
55. Hahn, A.F., Feasby, T.E., Wilkie, L., Lovgren, D. (1993). Anti-Galactocerebroside antibody (Gal-C AB) increases demyelination in adoptive transfer experimental allergic neuritis. Presented at the American Academy of Neurology Meeting, New York

56. Watling, C, Hahn, A.F., Feasby, T.E., Elleker, M.B. (1993). Chronic inflammatory demyelinating polyneuropathy (CIDP) in the setting of autoimmune glomerulonephritis. Presented at the Canadian Congress of Neurological Sciences meeting, Toronto
57. Hahn, A.F., Feasby, T.E., Wilkie, L., Lovgren, D. (1993). Axonal Degeneration in Non-immune Demyelination. Presented at the American Neurological Association meeting, Boston
58. A.F. Hahn, C.F. Bolton, M. Vandervoort, N. Pillay, C. Chalk, T. Benstead, V. Bril, T.E. Feasby (1994). Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy (CIDP) : a double-blind, sham-controlled cross-over study. Presented at the American Neurological Association June 29-30
59. Moulin, D., Hagen, N., Feasby, T.E., Amireh, R., Hahn, A.F. (1994). Pain in Guillain-Barré Syndrome. Presented at the American Academy of Neurology Meeting, Seattle
60. Hahn, A.F., Bolton, C.F., Vandervoort, M., Feasby, T.E., Zochodne, D.W. (1995). Intravenous immunoglobulin treatment (IVIG) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A double blind, placebo-controlled cross-over study. Presented at the American Academy of Neurology Meeting, Seattle
61. Hahn, A.F., Bolton, C.F., Vandervoort, M., Pillay, N., Chalk, C., Benstead, T., Bril, V., Feasby, TE (1995). Plasma exchange therapy in Chronic Inflammatory Demyelinating Polyneuropathy: a double-blind, sham-controlled cross-over study. *Ann Neurol.* 38, 303
62. PSGBS Trialists (presented by T.E. Feasby) (1995). Comparison of Plasma exchange, intravenous immunoglobulin and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barré Syndrome, American Neurological Association meeting, Washington, DC
63. Johnston, KC, Haley, EC, Jr. Li, JY, Feasby, TE, Lyden, PD, Adams, RJ, Hanson, SK, Faught, RE, Birmingham, AL (1997). Medical and neurological complications of ischemic stroke: experience from the RANTTAS Trial. *Neurology*, 48:8372-8373
64. Janes, E, Ghali, W, Karbalai, H, Feasby, TE, Buchan, AM (1998). The risks of inappropriate carotid endarterectomy. American Neurological Association, Montreal, *Ann Neurol.* 44:510
65. Ashworth, NL, Zochodne, DW, Hahn, AF, Bolton, CF, Pillay, N, Chalk, CH, Benstead, TJ, Bril, V, Feasby, TE. (1998). The impact of plasma exchange on indices of primary demyelination in chronic inflammatory demyelinating polyneuropathy. American Association of Electrodiagnostic Medicine meeting, Orlando, FL
66. Karbalai, H, Demchuk, A, Hoyte, K, Klein, G, Feasby, TE, Buchan, AM. (1999). Effectiveness of tissue-type plasminogen activator for acute ischemic stroke: consequences of protocol violation. Presented at the American Heart Association International Conference on Stroke and Cerebral Circulation, Nashville, TN

67. Feasby, TE. (1999). Measuring the Effectiveness of Neurological Treatment. Presented at the American Academy of Neurology Meeting, Toronto, Ontario, April 1999; *Neurology*;52:A142
68. Federico, P, Zochodne, DW, Feasby, TE. (1999). Intravenous immunoglobulin treatment in Multifocal Motor Neuropathy with Conduction Block: a double-blind, placebo-controlled, cross-over study. Presented at the American Academy of Neurology Meeting, Toronto, Ontario, April 1999; *Neurology*;52:A127
69. Feasby, TE. (1999). Is appropriateness an appropriate process measure for carotid endarterectomy? Presented at the American Neurological Association Meeting, Seattle, October 10, 1999, *Ann. Neurol.* 46:501-502.
70. Feasby, TE, Quan, H, Ghali, WA (2002) Hospital and surgeon determinants of carotid endarterectomy outcome. Presented at the American Academy of Neurology meeting, Denver, Colorado, April 2002.
71. Kennedy, J, Quan, H, Ghali, WA, Feasby, TE. (2002) Appropriateness studies in carotid endarterectomy must take account of the imaging modality used. Presented at the American Neurological Association Meeting, New York, October 13, 2002, *Ann Neurol* Sept 2002.
72. Feasby, TE, Quan, H, Ghali, WA. (2003) Provincial outcomes of carotid endarterectomy. Presented at the 28th International Stroke Conference of the American Stroke Association, Phoenix, Arizona, February 14, 2003, *Stroke* January 2003.
73. Kennedy, J, Quan, H, Ghali, WA, Feasby, TE. (2003) Health system factors and the appropriateness of endarterectomy. Presented at the CIHR Institute of Health Services and Policy Research Symposium, Montreal (Prize for 3rd best poster)
74. Kennedy, J, Quan, H, Ghali, WA, Feasby, TE. (2004) Health system factors and the appropriateness of endarterectomy. Presented at the 29th International Stroke Conference of the American Stroke Association, San Diego, February 6, 2004.
75. Girard, LP, Eliasziw, M, Quan, H, Kennedy, J, Feasby, TE, Ghali, WA. (2006) Complication rates after left vs. right-sided carotid endarterectomy: evidence from multiple sources. Presented at the 7th Scientific forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington, DC, May 8, 2006.
76. Jason W. Busse, John J. Riva, Raja Rampersaud, Gordon H. Guyatt, Michael J. Goytan, Thomas E. Feasby, Martin Reed, John You. Imaging Practices for Spine-Related Complaints Referred for Surgical Assessment: A Survey of Canadian Spine Surgeons. Canadian Spine Society Meeting, Quebec City, February 2013
77. Busse JW, Alexander PE, Abdul-Razzak A, Riva JJ, Alabousi M, Dufton J, Li R, Kagoma Y, Zhang M, Faulhaber M, Couban R, Guyatt GH, Rampersaud YR, Goytan MJ, Lloyd N, DeMone B, Feasby TE, Reed M, Mills EJ, Thorlund K, Schünemann H, You J. Appropriateness of Spine-Related Imaging Use. Oral presentation at the 2013 CADTH Symposium. St. John's, NFLD, Canada. May 6, 2013.

78. Verboon, C,Feasby, TE,Jacobs, BC, for the IGOS Consortium. International Guillain-Barre Syndrome Outcome Study (IGOS): A prospective INC study on clinical and biological predictors of disease course and outcome. Presented at the Peripheral Nerve Society meeting, Mt. Ste. Anne, Quebec, June 30, 2015.
79. Van den Berg, B....Feasby, TE...et al. The International Guillain-Barre Study (IGOS): A prospective study of clinical and biological predictors of disease course and outcome. Inflammatory Neuropathy Consortium (INC) meeting, Glasgow, June 2016
80. Feasby, TE. The Axonal Form of Guillain-Barre Syndrome. Presented at the Inflammatory Neuropathy Consortium (INC) meeting in Glasgow in June 2016
81. Yavin D, Isaacs AM, Casha S, Wiebe S, Feasby TE, Atta C, Holroyd-Leduc J, Hurlbert RJ, Quan H, Nataraj A, Sutherland GR, Jette N. Lumbar fusion for degenerative disease: a systematic review and meta-analysis. Canadian Congress of Neurological Sciences, Quebec City, QC. *Canadian Journal of Neurological Sciences*. 2016;43(suppl 2):S50
82. Yavin D, Casha S, Wiebe S, Feasby TE, Holroyd-Leduc J, Hurlbert RJ, Quan H, Nataraj A, Sutherland GR, Bartleson JD, Christie S, Davenport WJ, Findlay T, Fleetwood IG, Furlan A, Gallagher C, Mukhida K, Ouellet JA, O'Toole J, Reitman CA, Shamji MF, Williamson O, Dhaliwal P, du Plessis S, Jette N. Lumbar Spine Fusion: A RAND/UCLA Appropriateness Study. Annual Meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves (Las Vegas, NV). Mar 2017 (oral presentation) *Neurosurg Focus* 2017;